Streetbeat News

SCPH

scPharmaceuticals Inc.

https://www.scpharmaceuticals.com

Industry

Biotechnology

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Open

4.33

Mkt cap

210M

Volume

174K

High

4.40

P/E Ratio

-2.70

52-wk high

6.71

Low

4.18

Div yield

N/A

52-wk low

3.24

scPharmaceuticals is set to announce its third quarter 2024 financial results on November 13, 2024. A conference call and webcast will be hosted by management after the market closes at 4:30 p.m. ET.

Portfolio Pulse from

November 06, 2024 | 9:15 pm

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on scPharmaceuticals (NASDAQ:SCPH) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 10:51 am

scPharmaceuticals reported a Q2 EPS of $(0.36), an improvement from $(0.44) year-over-year. Revenue increased significantly to $8.1 million from $1.6 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 8:02 pm

scPharmaceuticals Inc. (NASDAQ:SCPH) announced a $50 million public offering of 12 million shares of common stock at $4 per share. The offering includes pre-funded warrants and is expected to close on August 13, 2024. Leerink Partners and TD Cowen are joint book-running managers.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 1:53 pm

scPharmaceuticals Inc. (NASDAQ:SCPH) received FDA approval for expanded use of Furoscix to include NYHA Class IV heart failure patients. The company also secured $125 million in non-dilutive financing to support commercialization efforts and released positive topline results from a pharmacokinetic study of SCP-111. Additionally, scPharmaceuticals announced a proposed public offering of shares and pre-funded warrants.

Portfolio Pulse from Vandana Singh

August 12, 2024 | 1:02 pm

scPharmaceuticals has announced a proposed underwritten public offering of common stock and pre-funded warrants. The details of the offering have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:10 am

scPharmaceuticals announced non-dilutive financings totaling up to $125 million from Perceptive Advisors. The company received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million. The term loan refinances existing debt principal, lowers the coupon, extends the interest-only period for four additional years, and lowers the minimum cash requirement to $5 million.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:08 am

The FDA has approved scPharmaceuticals' supplemental new drug application to expand the indication for Furoscix. Previously indicated for NYHA Class II and III chronic heart failure patients, Furoscix can now be used for all classes, including Class IV.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:06 am

scPharmaceuticals announced positive topline results from the pharmacokinetic study of SCP-111, a low volume, pH-neutral formulation of furosemide administered via an autoinjector. SCP-111 demonstrated high bioavailability and similar efficacy to IV furosemide with minimal pain and manageable adverse events.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:04 am

scPharmaceuticals Inc. (NASDAQ:SCPH) announced that the FDA has accepted its Supplemental New Drug Application (sNDA) to expand the indication of FUROSCIX to include treatment of edema in patients with chronic kidney disease (CKD). The FDA has set a target action date of March 6, 2025, and no additional clinical studies are required.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.